Non-Small Cell Lung Cancer - Metastatic

1st line

Squamous

IRB# 18114
BrightPath
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with PD-L1+ Non-Small Cell Lung Cancer

Non-squamous

IRB# 18114
BrightPath
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with PD-L1+ Non-Small Cell Lung Cancer

2nd/3rd Line

IRB# 11046
BrightPath
Lung-MAP: Study involving multiple drugs

Correlatives

No Trials Currently Available

IRB# 11046
Lung-MAP: Study involving multiple drugs

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php